T. Rowe Price Associates
LHDX

T. Rowe Price Associates’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

T. Rowe Price Associates’s Portfolio LHDX Stock Details LHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,400
Closed -$32K – 3072
2022
Q2 		$32K Hold
17,400
– – ﹤0.01% 2907
2022
Q1 		$62K Hold
17,400
– – ﹤0.01% 2906
2021
Q4 		$150K Buy
17,400
+7,200
+71% +$45.8K ﹤0.01% 2812
2021
Q3 		$78K Sell
10,200
-4,600
-31% -$38.8K ﹤0.01% 2874
2021
Q2 		$98K Buy
+14,800
New +$93.3K ﹤0.01% 2851

Other funds holding LHDX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
EV
Eclipse Ventures Palo Alto, California $39.6M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $157B AUM 32.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $100M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
LRPA
L. Roy Papp & Associates Phoenix, Arizona $867M AUM 16.97% 1-Year Est. Return
CWA
Consilio Wealth Advisors Bellevue, Washington $342M AUM 17.59% 1-Year Est. Return